Advertisement

Financing › Details
908 Devices–SEVERAL: investment, 202012 IPO $130m+$19.5m net $136.6m with 6.5m+975k shares common stock at $20/share at Nasdaq Global Market
![]() |
Period | 2020-12-18 |
![]() |
Region | United States (USA) |
Predecessor | 908 Devices–SEVERAL: investment, 201904 financing round Series E $17.5m led by new investor Northpond Ventures | |
![]() |
Money taker | 908 Devices Inc. (Nasdaq: MASS) |
Group | 908 Devices (Group) | |
Money source | SEVERAL | |
![]() |
Product | high-pressure mass spectrometry (HPMS™ technology) |
Product 2 | investment banking | |
908 Devices, Inc.. (12/18/20). "Press Release: 908 Devices Announces Pricing of Initial Public Offering".
908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of its upsized initial public offering of shares of its common stock, with 6,500,000 shares being offered by the Company at a public offering price of $20.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 975,000 shares of common stock from the Company at the public offering price. The shares are expected to begin trading on the Nasdaq Global Market on December 18, 2020 under the ticker symbol “MASS.” The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses payable by 908 Devices are expected to be $130.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 22, 2020, subject to the satisfaction of customary closing conditions.
Cowen and SVB Leerink acted as lead book-running managers for the proposed offering. William Blair and Stifel acted as book-running managers for the proposed offering.
A registration statement on Form S-1 relating to the shares sold in the initial public offering has been filed with the Securities and Exchange Commission and became effective on December 17, 2020. The offering will be made only by means of a prospectus, copies of which may be obtained from: Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 833-297-2926, or by email at PostSaleManualRequests@broadridge.com; or SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, Massachusetts 02120, telephone: 1-800-808-7525, ext. 6132, or by email at syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Record changed: 2024-12-20 |
Advertisement

More documents for 908 Devices (Group)
- [1] 908 Devices, Inc.. (8/9/22). "Press Release: 908 Devices Acquires Trace Analytics, Enabling On-line Bioanalytics". Boston, MA....
- [2] 908 Devices, Inc.. (3/7/22). "Press Release: 908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook". Boston, MA....
- [3] 908 Devices, Inc.. (3/2/22). "Press Release: 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to Its Board of Directors"....
- [4] 908 Devices, Inc.. (1/7/22). "Press Release: 908 Devices Announces GSK Purchases Fifth Rebel Cell Culture Media Analyzer". Boston, MA....
- [5] 908 Devices, Inc.. (6/22/21). "Press Release: 908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights". Boston, MA....
- [6] 908 Devices, Inc.. (12/18/20). "Press Release: 908 Devices Announces Pricing of Initial Public Offering"....
- [7] 908 Devices, Inc.. (8/12/19). "Press Release: 908 Devices Launches the Rebel, the First At-line Spent Cell Media Analyzer for Bioprocess Labs". Boston, MA....
- [8] 908 Devices, Inc.. (7/25/19). "Press Release: 908 Devices Poised to Modernize Upstream Bioprocess Analytics with a Grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)". Boston, MA....
- [9] 908 Devices, Inc.. (6/14/19). "Press Release: 908 Devices Addresses Emerging Novichok Nerve Agent Threat, Expands Capabilities for MX908 Chemical Detection Device". Boston, MA....
- [10] 908 Devices, Inc.. (6/3/19). "Press Release: 908 Devices Broadens the ZipChip Platform, Brings New Capability to Biotherapeutics Researchers". Boston, MA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement

» top